Systemic Therapy for Hepatocellular Carcinoma
First-line treatment for HCC in patients with preserved liver function
Second-line treatment for individuals with disease progression or intolerance to first-line systemic therapy
Systemic therapy for HCC in patients with poor liver function
Systemic therapy for HCC as adjuvant therapy
Recommendation Grading
Overview
Title
Systemic Therapy for Hepatocellular Carcinoma
Authoring Organization
American Gastroenterological Association
Publication Month/Year
February 20, 2022
Last Updated Month/Year
September 4, 2024
Supplemental Implementation Tools
Document Type
Guideline
Country of Publication
US
Document Objectives
Hepatocellular carcinoma (HCC), the most common primary liver cancer, remains a deadly cancer, with an incidence that has tripled in the United States since 1980. In recent years, new systemic therapies for HCC have been approved and a critical assessment of the existing data is necessary to balance benefits and harms and inform the development of evidence-based guidelines.
Inclusion Criteria
Male, Female, Adult, Infant
Health Care Settings
Ambulatory, Outpatient, Operating and recovery room
Intended Users
Nurse, nurse practitioner, physician, physician assistant
Scope
Treatment, Management
Diseases/Conditions (MeSH)
D006528 - Carcinoma, Hepatocellular
Keywords
systemic therapy, hepatocellular carcinoma, liver cancer, hcc
Source Citation
Grace L. Su, Osama Altayar, Robert O’Shea, Raj Shah, Bassam Estfan, Candice Wenzell, Shahnaz Sultan, Yngve Falck-Ytter, AGA Clinical Practice Guideline on Systemic Therapy for Hepatocellular Carcinoma, Gastroenterology, Volume 162, Issue 3, 2022, Pages 920-934, ISSN 0016-5085, https://doi.org/10.1053/j.gastro.2021.12.276.